The Tylenol acetaminophen-autism mass tort is one of the most prominent emerging dockets. The litigation, consolidated as MDL 3043 in the Southern District of New York in October 2022, alleges that prenatal acetaminophen exposure (Tylenol and generic equivalents) causes elevated rates of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children.
The docket has faced significant Daubert challenges — in December 2023, the federal court excluded several of the plaintiffs' general causation experts, substantially constraining the litigation. The case has continued through appeals and state-court parallel proceedings. The path to settlement infrastructure remains uncertain.
Highfloor supports light-cadence exploratory flights for firms positioning early in the docket. Heavy qualification flights are typically premature given the unsettled scientific and procedural status. Per-firm decisions on flight intensity should be made carefully with mass tort counsel.
- Light-cadence exploratory flights only
- Bar TV awareness layer (avoid heavy qualification spend until docket matures)
- Search-keyword spend on Tylenol-autism-specific terms
- Direct mail to qualifying-population data lists where applicable
- October 2022 — JPML consolidates to MDL 3043 (S.D. New York)
- December 2023 — federal court Daubert ruling excluding several plaintiff experts
- 2024–2025 — continued appeals and state-court parallel proceedings
- Distributed broadly — broad eligibility population
- Particular concentration in metros with strong family-decision-maker demographic